FDA Approves Omisirge to Treat Patients with Severe Aplastic Anemia @AAMDSIF
FDA Approves Omisirge to Treat Patients with Severe Aplastic Anemia @AAMDSIF
Uploaded May 2026 | Updated September 2026, 2 hours ago
Learn from Dr. Richard Childs, RADM, as he explains the FDA approval of Omnisirge for treating patients with Severe Aplastic Anemia, or SAA.
FDA Approves Omisirge to Treat Patients with Severe Aplastic AnemiaPredisposition to Inherited Bone Marrow Failure Syndromes from Patient & Family Conference UT 2023Living Well with Bone Marrow Failure Disease from the 2022 Buffalo Patient and Family ConferenceGetting the Right Diagnosis from the 2023 New Haven Patient and Family ConferenceAdvances in the Science and Treatment of PNHAplastic Anemia and Non-Transplant TherapiesPNH Non-Transplant Therapies and Management -2023 Omaha Patient -Family Hybrid ConferenceSymposium Summary Rich Stone and Neal Young2023 EHA/ASCO Updates: MDS and AMLLiving with PNH - 2022 Memphis Patient & Family ConferenceHolistic Care: Expert Panel Discussion from the 2023 3-City Tandem Patient and Family ConferencesAsk the AML (Acute Myeloid Leukemia) Expert with Dr. Salman Fazal - 2023 Webinar
AAMDSIF |

FDA Approves Omisirge to Treat Patients with Severe Aplastic Anemia

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER